Literature DB >> 2689350

ELISA for antibodies to lipid A, lipopolysaccharides and other hydrophobic antigens.

M A Freudenberg1, A Fomsgaard, I Mitov, C Galanos.   

Abstract

A simple, sensitive and rapid ELISA method for the quantification and characterization of antibodies to lipid A has been developed, which can also be applied to other hydrophobic antigens. For coating, antigens were applied to the wells of ELISA plates as solutions in a mixture of chloroform and ethanol 1:9 (v/v), and the solvent evaporated in a stream of warm air. Under these conditions a high coating efficiency was achieved, which made the assay highly sensitive. The use of the above organic solvent considerably reduced the nonspecific adsorption of immunoglobulins to the solid phase, making the usual blocking of unspecific binding sites with BSA or gelatine unnecessary. For screening of lipid A antibodies in the sera of immunized animals, coating with 0.2 microgram of the corresponding antigen per well was found to be suitable. For optimal measurement of antibodies in pre-immune sera, sera of healthy human donors, and of monoclonal antibodies, higher amounts of antigen (1-2 micrograms/well) had to be used. The coating method described here proved excellent also for other antigens directly soluble in organic solvents, such as Re-lipopolysaccharide (LPS) or gangliosides. In addition, the method was successfully applied to less hydrophobic antigens, such as LPS of the classes Ra to Rd and S forms, and lipoteichoic acid. These could be brought into solution in chloroform/ethanol by diluting their aqueous solutions with a large volume of the organic mixture.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2689350     DOI: 10.1007/bf01650719

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  22 in total

1.  [Production of antisera against somatic (O) antigens of Salmonella. 3. Investigations on precipitating antisera].

Authors:  S Schlecht; O Westphal
Journal:  Zentralbl Bakteriol Orig       Date:  1968

2.  A new method for the extraction of R lipopolysaccharides.

Authors:  C Galanos; O Lüderitz; O Westphal
Journal:  Eur J Biochem       Date:  1969-06

3.  [Lipoid A antibody titer in the human].

Authors:  W Marget
Journal:  Infection       Date:  1987 Mar-Apr       Impact factor: 3.553

4.  Parameters affecting the enzyme-linked immunosorbent assay of immunoglobulin G antibody to a rough mutant of Salmonella minnesota.

Authors:  S C Bruins; I Ingwer; M L Zeckel; A C White
Journal:  Infect Immun       Date:  1978-09       Impact factor: 3.441

5.  Determination of anti-lipid A and lipid A by enzyme immunoassay.

Authors:  P C Fink; C Galanos
Journal:  Immunobiology       Date:  1981       Impact factor: 3.144

6.  An enzyme-linked immunosorbent assay (ELISA) for the measurement of antibodies to different parts of the gram-negative lipopolysaccharide core region.

Authors:  B J Appelmelk; A M Verweij-Van Vught; D M MacLaren; L G Thijs
Journal:  J Immunol Methods       Date:  1985-10-10       Impact factor: 2.303

7.  [Antibodies to lipoid A in the treatment of septic shock].

Authors:  L Jaspers; W Marget; P J Mar; K Hoffmann; P Langecker; G Ruckdeschel; A Obermeier; E Kastenbauer
Journal:  Infection       Date:  1987 Mar-Apr       Impact factor: 3.553

8.  Age-related prevalence of human serum IgG and IgM antibody to the core glycolipid of Escherichia coli strain J5, as measured by ELISA.

Authors:  B J Law; M I Marks
Journal:  J Infect Dis       Date:  1985-06       Impact factor: 5.226

9.  Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli.

Authors:  E J Ziegler; J A McCutchan; J Fierer; M P Glauser; J C Sadoff; H Douglas; A I Braude
Journal:  N Engl J Med       Date:  1982-11-11       Impact factor: 91.245

10.  Immunogenic properties of lipid A.

Authors:  C Galanos; M A Freudenberg; F Jay; D Nerkar; K Veleva; H Brade; W Strittmatter
Journal:  Rev Infect Dis       Date:  1984 Jul-Aug
View more
  20 in total

1.  Characterization of the epitope specificity of murine monoclonal antibodies directed against lipid A.

Authors:  H M Kuhn; L Brade; B J Appelmelk; S Kusumoto; E T Rietschel; H Brade
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

2.  Bactericidal monoclonal antibody against Moraxella catarrhalis lipooligosaccharide cross-reacts with Haemophilus Spp.

Authors:  Raina T Gergova; Ianko D Iankov; Iana H Haralambieva; Ivan G Mitov
Journal:  Curr Microbiol       Date:  2007-01-05       Impact factor: 2.188

3.  alpha-GlcNAc-1-->2-alpha-glc, the Salmonella homologue of a conserved lipopolysaccharide motif in the Enterobacteriaceae, elicits broadly cross-reactive antibodies.

Authors:  N A Nnalue
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

4.  Efficacy of tumor cell vaccine after incorporating monophosphoryl lipid A (MPL) in tumor cell membranes containing tumor-associated ganglioside.

Authors:  M H Ravindranath; S M Brazeau; D L Morton
Journal:  Experientia       Date:  1994-07-15

5.  Specific IgG2 antibodies to Pseudomonas aeruginosa lipid A and lipopolysaccharide are early markers of chronic infection in patients with cystic fibrosis.

Authors:  G Kronborg; T Pressler; A Fomsgaard; C Koch; N Høiby
Journal:  Infection       Date:  1993 Sep-Oct       Impact factor: 3.553

6.  Cross-reactivity of monoclonal antibodies and sera directed against lipid A and lipopolysaccharides.

Authors:  H M Kuhn
Journal:  Infection       Date:  1993 May-Jun       Impact factor: 3.553

7.  Characterization of specific binding of a human immunoglobulin M monoclonal antibody to lipopolysaccharide and its lipid A domain.

Authors:  Y Fujihara; M G Lei; D C Morrison
Journal:  Infect Immun       Date:  1993-03       Impact factor: 3.441

8.  Antibody responses to lipid A, core, and O sugars of the Pseudomonas aeruginosa lipopolysaccharide in chronically infected cystic fibrosis patients.

Authors:  G Kronborg; A Fomsgaard; C Galanos; M A Freudenberg; N Høiby
Journal:  J Clin Microbiol       Date:  1992-07       Impact factor: 5.948

9.  A fusion intermediate gp41 immunogen elicits neutralizing antibodies to HIV-1.

Authors:  Rachel P J Lai; Miriam Hock; Jens Radzimanowski; Paul Tonks; David Lutje Hulsik; Gregory Effantin; David J Seilly; Hanna Dreja; Alexander Kliche; Ralf Wagner; Susan W Barnett; Nancy Tumba; Lynn Morris; Celia C LaBranche; David C Montefiori; Michael S Seaman; Jonathan L Heeney; Winfried Weissenhorn
Journal:  J Biol Chem       Date:  2014-08-26       Impact factor: 5.157

10.  Using distinct molecular signatures of human monocytes and dendritic cells to predict adjuvant activity and pyrogenicity of TLR agonists.

Authors:  Richard Kenmoe Kamgang; Inês Ramos; Lurdes Rodrigues Duarte; Mascia Ghielmetti; Marina Freudenberg; Clemens Dahinden; Elisabetta Padovan
Journal:  Med Microbiol Immunol       Date:  2008-02-19       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.